Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Income towards Parent Company (2016 - 2020)

Historic Income towards Parent Company for Phio Pharmaceuticals (PHIO) over the last 9 years, with Q4 2020 value amounting to -$2.5 million.

  • Phio Pharmaceuticals' Income towards Parent Company rose 775.57% to -$2.5 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$2.5 million, marking a year-over-year increase of 7264.44%. This contributed to the annual value of -$11.5 million for FY2022, which is 1359.98% up from last year.
  • As of Q4 2020, Phio Pharmaceuticals' Income towards Parent Company stood at -$2.5 million, which was up 775.57% from -$2.3 million recorded in Q3 2020.
  • Phio Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$1.5 million during Q3 2018, with a 5-year trough of -$5.5 million in Q1 2017.
  • Over the past 5 years, Phio Pharmaceuticals' median Income towards Parent Company value was -$2.2 million (recorded in 2016), while the average stood at -$2.3 million.
  • As far as peak fluctuations go, Phio Pharmaceuticals' Income towards Parent Company tumbled by 14473.33% in 2017, and later surged by 5899.27% in 2018.
  • Over the past 5 years, Phio Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$2.3 million in 2016, then rose by 14.41% to -$2.0 million in 2017, then grew by 13.74% to -$1.7 million in 2018, then crashed by 54.55% to -$2.7 million in 2019, then increased by 7.76% to -$2.5 million in 2020.
  • Its Income towards Parent Company was -$2.5 million in Q4 2020, compared to -$2.3 million in Q3 2020 and -$1.7 million in Q2 2020.